Trial Profile

A Phase I Study of Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LMB 100 (Primary) ; Tofacitinib (Primary)
Indications Adenocarcinoma; Appendiceal cancer; Biliary cancer; Cholangiocarcinoma; Mesothelioma; Pancreatic cancer; Solid tumours
Focus Adverse reactions; Pharmacokinetics

13 Jul 2023 Status changed from active, no longer recruiting to completed.
06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
29 Sep 2021 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com